

## Supplemental Online Content

Janczewski LM, Cotler J, Merkow RP, et al. Alterations in cancer treatment during the first year of the COVID-19 pandemic in the US. *JAMA Netw Open*. 2023;6(10):e2340148. doi:10.1001/jamanetworkopen.2023.40148

**eFigure 1.** Consort Diagram

**eTable 1.** Changes in Age of Treated Patients by Cancer Site in the Year 2020

**eTable 2.** Travel Distance in Miles by Cancer Site in the Year 2020

**eTable 3.** Coordination of Care Received at Single Versus Multiple Institutions by Cancer Site in the Year 2020

**eTable 4.** Utilization of Treatment in the Year 2020 Compared With Prior Years


**eTable 5.** Utilization of Treatment by Facility Type During the COVID-19 Pandemic

**eFigure 2.** Number of Hospitals per Facility Type in the NCDB

**eFigure 3.** Utilization of Treatment in the Year 2020 Compared With Prior Years by Primary Site

This supplemental material has been provided by the authors to give readers additional information about their work.

**eFigure 1.** Consort Diagram



**eTable 1.** Changes in Age of Treated Patients by Cancer Site in the Year 2020

Primary Site	Age at Diagnosis (years)	Observed No. (%)	Expected No. (% [95% CI])	Corrected p-Value	Observed - Expected	% Decrease in 2020
All Sites Combined	18 - 39	61,728 (5.0)	79,615 (5.4 [5.3,5.4])	<.001	-17887	22.47
	40 - 49	96,112 (7.8)	121,249 (8.2 [8.1,8.2])	<.001	-25137	20.73
	50 - 59	214,985 (17.5)	267,842 (18.1 [18.0,18.2])	<.001	-52857	19.73
	60 - 69	370,356 (30.1)	434,876 (29.4 [29.3,29.5])	<.001	-64520	14.84
	70 - 79	324,119 (26.4)	371,699 (25.1 [25.0,25.2])	<.001	-47580	12.80
	80 - 89	139,168 (11.3)	168,686 (11.4 [11.3,11.4])	0.03	-29518	17.50
	90 +	23,186 (1.9)	35,970 (2.4 [2.4,2.5])	<.001	-12784	35.54
Breast	18 - 39	10,812 (4.6)	13,063 (4.7 [4.7,4.8])	0.09	-2251	17.23
	40 - 49	32,857 (14.1)	38,953 (14.1 [14.0,14.3])	>.99	-6096	15.65
	50 - 59	51,070 (21.9)	60,448 (21.9 [21.8,22.1])	>.99	-9378	15.51
	60 - 69	66,897 (28.7)	77,875 (28.3 [28.1,28.4])	<.001	-10978	14.10
	70 - 79	51,707 (22.2)	58,854 (21.4 [21.2,21.5])	<.001	-7147	12.14
	80 - 89	17,333 (7.4)	21,485 (7.8 [7.7,7.9])	<.001	-4152	19.33
	90 +	2,655 (1.1)	4,749 (1.7 [1.7,1.8])	<.001	-2094	44.10
Colon	18 - 39	3,137 (3.6)	3,396 (3.3 [3.1,3.4])	<.001	-259	7.63
	40 - 49	7,952 (9.0)	8,768 (8.4 [8.2,8.6])	<.001	-816	9.31
	50 - 59	17,349 (19.7)	21,122 (20.2 [20.0,20.5])	<.001	-3773	17.86
	60 - 69	22,881 (26.0)	27,423 (26.3 [26.0,26.5])	0.43	-4542	16.56
	70 - 79	20,653 (23.5)	24,505 (23.5 [23.2,23.7])	>.99	-3852	15.72
	80 - 89	13,172 (15.0)	15,684 (15.0 [14.8,15.2])	>.99	-2512	16.02
	90 +	2,852 (3.2)	3,448 (3.3 [3.2,3.4])	>.99	-596	17.27
Lung	18 - 39	779 (0.5)	1,405 (0.8 [0.8,0.8])	<.001	-626	44.54
	40 - 49	3,204 (2.2)	4,391 (2.5 [2.4,2.6])	<.001	-1187	27.02
	50 - 59	18,621 (12.7)	23,654 (13.6 [13.4,13.7])	<.001	-5033	21.28
	60 - 69	48,389 (33.1)	55,068 (31.6 [31.4,31.9])	<.001	-6679	12.13
	70 - 79	51,207 (35.0)	59,889 (34.4 [34.2,34.6])	<.001	-8682	14.50
	80 - 89	21,461 (14.7)	26,152 (15.0 [14.9,15.2])	0.002	-4691	17.94
	90 +	2,454 (1.7)	3,519 (2.0 [2.0,2.1])	<.001	-1065	30.27
Melanoma	18 - 39	3,643 (7.0)	5,166 (7.6 [7.4,7.8])	<.001	-1523	29.48
	40 - 49	4,438 (8.6)	6,043 (8.9 [8.7,9.1])	0.07	-1605	26.56
	50 - 59	8,397 (16.2)	11,455 (16.8 [16.6,17.1])	<.001	-3058	26.70

	<b>60 - 69</b>	14,025 (27.1)	17,759 (26.1 [25.8,26.4])	<.001	-3734	21.03
	<b>70 - 79</b>	13,542 (26.1)	16,769 (24.7 [24.3,25.0])	<.001	-3227	19.24
	<b>80 - 89</b>	6,621 (12.8)	8,708 (12.8 [12.6,13.1])	>.99	-2087	23.97
	<b>90 +</b>	1,166 (2.2)	2,098 (3.1 [3.0,3.2])	<.001	-932	44.44
<b>Stomach</b>	<b>18 - 39</b>	547 (3.4)	676 (3.5 [3.3,3.8])	>.99	-129	19.03
	<b>40 - 49</b>	1,133 (7.0)	1,396 (7.3 [6.9,7.7])	0.75	-263	18.82
	<b>50 - 59</b>	2,625 (16.2)	3,150 (16.5 [16.0,17.0])	>.99	-525	16.67
	<b>60 - 69</b>	4,609 (28.4)	5,346 (28.0 [27.4,28.6])	>.99	-737	13.79
	<b>70 - 79</b>	4,497 (27.7)	5,153 (27.0 [26.4,27.6])	0.27	-656	12.72
	<b>80 - 89</b>	2,357 (14.5)	2,808 (14.7 [14.2,15.2])	>.99	-451	16.04
	<b>90 +</b>	460 (2.8)	562 (2.9 [2.7,3.2])	>.99	-102	18.09

**eTable 2.** Travel Distance in Miles by Cancer Site in the Year 2020

Primary Site	Travel Distance	Observed No. (%)	Expected No. (% [95% CI])	Corrected p-Value	Observed - Expected	% Decrease in 2020
All Sites Combined	Within 5 miles	308,030 (25.1)	371,244 (25.1 [25.0,25.1])	>.99	-63214	17.03
	5-10 miles	263,786 (21.5)	313,359 (21.2 [21.1,21.2])	<.001	-49573	15.82
	10-15 miles	170,048 (13.8)	203,254 (13.7 [13.7,13.8])	0.003	-33206	16.34
	15-35 miles	271,432 (22.1)	322,145 (21.7 [21.7,21.8])	<.001	-50713	15.74
	> 35 miles	216,358 (17.6)	271,247 (18.3 [18.2,18.4])	<.001	-54889	20.24
Breast	Within 5 miles	63,667 (27.3)	75,954 (27.5 [27.4,27.7])	0.06	-12287	16.18
	5-10 miles	56,376 (24.2)	66,172 (24.0 [23.8,24.1])	0.17	-9796	14.80
	10-15 miles	35,511 (15.2)	41,974 (15.2 [15.1,15.3])	>.99	-6463	15.40
	15-35 miles	49,861 (21.4)	57,385 (20.8 [20.6,20.9])	<.001	-7524	13.11
	> 35 miles	27,916 (12.0)	34,531 (12.5 [12.4,12.6])	<.001	-6615	19.16
Colon	Within 5 miles	25,318 (28.8)	30,184 (28.9 [28.6,29.2])	>.99	-4866	16.12
	5-10 miles	20,148 (22.9)	23,565 (22.6 [22.3,22.8])	0.12	-3417	14.5
	10-15 miles	11,873 (13.5)	13,857 (13.3 [13.1,13.5])	0.3	-1984	14.32
	15-35 miles	17,828 (20.3)	21,130 (20.2 [20.0,20.5])	>.99	-3302	15.63
	> 35 miles	12,829 (14.6)	15,626 (15.0 [14.8,15.2])	0.005	-2797	17.90
Lung	Within 5 miles	39,503 (27.0)	47,646 (27.3 [27.1,27.6])	0.04	-8143	17.09
	5-10 miles	31,018 (21.2)	36,689 (21.1 [20.9,21.3])	0.56	-5671	15.46
	10-15 miles	19,126 (13.1)	22,597 (13.0 [12.8,13.1])	0.88	-3471	15.36
	15-35 miles	33,031 (22.6)	38,436 (22.1 [21.9,22.3])	<.001	-5405	14.06
	> 35 miles	23,437 (16.0)	28,851 (16.6 [16.4,16.7])	<.001	-5414	18.76
Melanoma	Within 5 miles	9,429 (18.2)	14,354 (19.3 [19.0,19.6])	<.001	-4925	34.31
	5-10 miles	9,935 (19.2)	14,018 (18.8 [18.6,19.1])	0.28	-4083	29.13
	10-15 miles	7,572 (14.6)	10,974 (14.7 [14.5,15.0])	>.99	-3402	31.00
	15-35 miles	13,610 (26.3)	19,087 (25.7 [25.3,26.0])	0.008	-5477	28.69
	> 35 miles	11,286 (21.8)	15,976 (21.5 [21.2,21.8])	0.46	-4690	29.35
Stomach	Within 5 miles	4,392 (27.1)	5,261 (27.6 [26.9,28.2])	0.69	-869	16.53
	5-10 miles	3,661 (22.6)	4,096 (21.5 [20.9,22.1])	0.004	-435	10.62
	10-15 miles	2,104 (13.0)	2,461 (12.9 [12.4,13.4])	>.99	-357	14.52
	15-35 miles	3,311 (20.4)	3,854 (20.2 [19.6,20.8])	>.99	-543	14.10
	> 35 miles	2,760 (17.0)	3,401 (17.8 [17.3,18.4])	0.03	-641	18.85
Other	Within 5 miles	165,721 (23.9)	198,704 (23.7 [23.6,23.8])	0.007	-32983	16.60

<b>5-10 miles</b>	142,648 (20.5)	169,883 (20.3 [20.2,20.4])	<.001	-27235	16.03
<b>10-15 miles</b>	93,862 (13.5)	112,496 (13.4 [13.4,13.5])	0.08	-18634	16.56
<b>15-35 miles</b>	153,791 (22.2)	183,126 (21.9 [21.8,21.9])	<.001	-29335	16.02
<b>&gt; 35 miles</b>	138,130 (19.9)	173,806 (20.7 [20.7,20.8])	<.001	-35676	20.53

**eTable 3.** Coordination of Care Received at Single Versus Multiple Institutions by Cancer Site in the Year 2020

Primary Site	Coordination of Care	Observed No. (%)	Expected No. (% [95% CI])	Corrected p-Value	Observed - Expected	% Decrease in 2020
All Sites Combined	Multiple	583,738 (47.5)	702,976 (47.7 [47.6,47.7])	<.001	-119238	16.96
	Single	592,763 (48.2)	693,483 (47.0 [46.9,47.1])	<.001	-100720	14.52
Breast	Multiple	137,994 (59.1)	161,106 (58.3 [58.1,58.5])	<.001	-23112	14.35
	Single	87,175 (37.4)	101,913 (36.9 [36.7,37.1])	<.001	-14738	14.46
Colon	Multiple	28,022 (43.1)	33,182 (43.2 [42.8,43.6])	>.99	-5160	15.55
	Single	34,493 (53.1)	40,486 (52.7 [52.4,53.1])	0.150	-5993	14.80
Lung	Multiple	60,849 (43.4)	73,132 (44.1 [43.9,44.4])	<.001	-12283	16.80
	Single	73,398 (52.3)	84,759 (51.2 [50.9,51.4])	<.001	-11361	13.40
Melanoma	Multiple	30,456 (58.0)	38,686 (56.4 [56.0,56.7])	<.001	-8230	21.27
	Single	19,960 (38.0)	26,226 (38.2 [37.8,38.6])	0.960	-6266	23.89
Stomach	Multiple	7,158 (54.0)	8,582 (54.5 [53.7,55.3])	0.710	-1424	16.59
	Single	5,471 (41.3)	6,266 (39.8 [39.0,40.6])	0.002	-795	12.68

**eTable 4.** Utilization of Treatment in the Year 2020 Compared With Prior Years


Primary Site	Treatment Modality	Observed No. (%)	Expected No. (% [95% CI])	Corrected p-Value	Observed - Expected	% Decrease in 2020
All Sites Combined	Surgery	702,480 (57.1)	849,285 (57.6 [57.5,57.7])	<.001	-146805	17.29
	Chemotherapy	392,860 (31.9)	460,874 (31.2 [31.2,31.3])	<.001	-68014	14.76
	Radiation	362,556 (29.5)	443,036 (30.0 [29.9,30.1])	<.001	-80480	18.17
Breast	Surgery	209,363 (89.7)	244,109 (88.3 [88.2,88.4])	<.001	-34746	14.23
	Chemotherapy	72,833 (31.2)	84,474 (30.5 [30.4,30.7])	<.001	-11641	13.78
	Radiation	121,876 (52.2)	144,760 (52.3 [52.1,52.4])	>.99	-22884	15.81
Colon	Surgery	52,586 (80.9)	62,947 (82.0 [81.7,82.3])	<.001	-10361	16.46
	Chemotherapy	25,462 (39.2)	29,291 (38.3 [38.0,38.7])	<.001	-3829	13.07
	Radiation	2,229 (3.4)	2,739 (3.6 [3.4,3.7])	0.180	-510	18.63
Lung	Surgery	32,543 (23.2)	40,975 (24.6 [24.4,24.8])	<.001	-8432	20.58
	Chemotherapy	56,120 (40.0)	66,283 (40.2 [39.9,40.4])	0.60	-10163	15.33
	Radiation	57,677 (41.1)	69,800 (41.8 [41.6,42.1])	<.001	-12123	17.37
Melanoma	Surgery	49,191 (93.6)	62,666 (92.0 [91.8,92.2])	<.001	-13475	21.50
	Chemotherapy	801 (1.5)	1,876 (2.8 [2.6,2.9])	<.001	-1075	57.30
	Radiation	1,580 (3.0)	2,716 (4.0 [3.8,4.1])	<.001	-1136	41.82
Stomach	Surgery	4,939 (37.3)	6,362 (40.6 [39.8,41.3])	<.001	-1423	22.36
	Chemotherapy	7,845 (59.2)	9,090 (58.4 [57.6,59.1])	0.170	-1245	13.70
	Radiation	3,229 (24.4)	3,999 (25.5 [24.8,26.2])	0.008	-770	19.27



**eTable 5.** Utilization of Treatment by Facility Type During the COVID-19 Pandemic

Primary Site	Facility Type	Observed No. (%)	Expected No. (% [95% CI])	Corrected p-Value	Observed - Expected	% Decrease in 2020	Decrease in Patients (n)
All Sites Combined	Academic/Research Program	449,529 (36.6)	554,622 (38.0 [38.0,38.1])	<.001	-105093	18.95	484
	Community Cancer Program	501,157 (40.8)	573,589 (39.3 [39.3,39.4])	<.001	-72432	12.63	99
	Integrated Network Program	276,752 (22.5)	317,579 (21.8 [21.7,21.8])	<.001	-40827	12.86	110
Breast	Academic/Research Program	72,590 (31.1)	87,484 (31.6 [31.5,31.8])	<.001	-14894	17.03	69
	Community Cancer Program	103,068 (44.2)	119,190 (43.1 [42.9,43.3])	<.001	-16122	13.53	22
	Integrated Network Program	57,079 (24.5)	66,295 (24.0 [23.8,24.1])	<.001	-9216	13.90	25
Colon	Academic/Research Program	18,285 (28.1)	22,370 (29.6 [29.2,29.9])	<.001	-4085	18.26	19
	Community Cancer Program	30,937 (47.6)	35,794 (47.3 [46.9,47.6])	<.001	-4857	13.57	7
	Integrated Network Program	15,654 (24.1)	17,500 (23.1 [22.8,23.4])	<.001	-1846	10.55	5
Lung	Academic/Research Program	42,312 (30.1)	53,153 (32.0 [31.8,32.2])	<.001	-10841	20.40	50
	Community Cancer Program	65,922 (47.0)	75,279 (45.3 [45.1,45.6])	<.001	-9357	12.43	13
	Integrated Network Program	31,881 (22.7)	36,857 (22.2 [22.0,22.4])	<.001	-4976	13.50	13
Stomach	Academic/Research Program	5,027 (37.9)	6,301 (40.5 [39.8,41.3])	<.001	-1274	20.22	6
	Community Cancer Program	5,256 (39.6)	5,856 (37.7 [36.9,38.4])	<.001	-600	10.24	1
	Integrated Network Program	2,952 (22.3)	3,300 (21.2 [20.6,21.9])	<.001	-348	10.56	1

**eFigure 2.** Number of Hospitals per Facility Type in the NCDB



**eFigure 3.** Utilization of Treatment in the Year 2020 Compared With Prior Years by Primary Site

